Study of the Absolute Oral Bioavailability of Dapagliflozin in Healthy Subjects

Completed · Phase 1

Conditions studied: Type 2 Diabetes Mellitus

In brief

The purpose of this study is to estimate the absolute oral bioavailability of dapagliflozin.

Key facts

Study ID

NCT00908271

Run by

AstraZeneca

People needed

7

Starts

2009-07-01

Expected to finish

2009-08-01

Last updated by the study team

2016-10-17

Who can join

Age: 18 and older, up to 45. Sex: male. Healthy volunteers: accepted.

You may qualify if…

• Healthy male subjects (ages 18 to 45) as determined by medical history, physical examination, 12-lead electrocardiogram (ECG), and clinical laboratory evaluations will be eligible to participate in the study

You may not qualify if…

• Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG or clinical laboratory determinations
• Participation in a radiolabeled investigational study drug trial within 12 months prior to admission to the clinical facility
• Exposure to significant radiation within 12 months prior to admission to the clinical facility

Where it is running

• Covance Clinical Research Unit, Inc. — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.